Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.
OPKO Health, Inc. (NASDAQ: OPK) has announced an R&D Day event scheduled for March 20, 2023, at 4:00 p.m. Eastern time. This two-hour virtual event will feature presentations from OPKO executives regarding ModeX Therapeutics' multispecific technology platforms, focusing on oncology and infectious diseases. Management will also discuss the MDX-2201 technology associated with a recently announced collaboration with Merck for a vaccine targeting Epstein-Barr virus. Attendees can access the live and archived webcast on OPKO’s Investor Relations website and participate in a Q&A session afterward.
OPKO Health announced an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, a preclinical nanoparticle vaccine targeting the Epstein-Barr virus (EBV). This vaccine aims to address the health challenges posed by EBV, including infectious mononucleosis and associated cancers. Under the agreement, OPKO will receive an upfront payment of $50 million and potential milestone payments totaling up to $872.5 million, in addition to royalties on global sales. The collaboration highlights ModeX's innovative multi-targeting approach and Merck's expertise in vaccine development.
OPKO Health, Inc. (NASDAQ: OPK) reported its fourth-quarter financial results for 2022, noting total revenues of $185.4 million, down from $401.3 million in 2021. The operating loss improved to $55.3 million from $63.1 million year-over-year. Significant highlights included revenue growth in pharmaceuticals, with product sales rising to $37.9 million, primarily from NGENLA® and RAYALDEE. However, diagnostics revenue plummeted to $139.4 million due to decreased COVID-19 testing. The net loss was $85.2 million, or $0.11 per share, compared to a net loss of $73.8 million in the prior year. Cash and cash equivalents stood at $153.2 million.
OPKO Health, Inc. (NASDAQ: OPK) is set to report its operating and financial results for the quarter ended December 31, 2022, on February 23, 2023, after U.S. markets close. The company's senior management will hold a conference call at 4:30 p.m. Eastern time to discuss the results and provide financial guidance. Interested participants are encouraged to pre-register for the call to receive immediate access, while a webcast will also be available for online viewing. Additionally, a telephone replay and webcast replay will be accessible until March 2, 2023. OPKO focuses on biopharmaceuticals and diagnostics within rapidly growing markets.